MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Enpatoran hydrochloride

產(chǎn)品活性：Enpatoran (M5049) hydrochloride 是一種有效的、具有口服活性的 TLR7/8 抑制劑，在HEK293 細胞中，其IC₅₀s 分別為 11.1 nM 和 24.1 nM。Enpatoran hydrochloride 對 TLR3, TLR4 和 TLR9 無活性。Enpatoran hydrochloride 可以阻斷分子合成配體和天然內(nèi)源性 RNA 配體。Enpatoran hydrochloride 在體內(nèi)的表現(xiàn)出良好的藥代動力學(xué)特性。Enpatoran hydrochloride 可用于先天性和適應(yīng)性自身免疫阻斷的相關(guān)研究。

研究領(lǐng)域：Immunology/Inflammation

作用靶點：Toll-like Receptor (TLR)

In Vitro: Enpatoran hydrochloride (0.01 nM-10 μM) inhibits production of IL-6 stimulated by all the ligands (miR-122, Let7c RNA, Alu RNA, and R848) with IC₅₀ values ranging from 35 to 45 nM.

In Vivo: Pre-treatment with Enpatoran hydrochloride (oral gavage; 1 mg/kg) before R848 (intraperitoneal injection of 25 µg) dose-dependently inhibits the production of IL-6 and IFN-α in mice.
Enpatoran hydrochloride exhibits high oral bioavailability (mouse 100%, rat 87%, dog 84%) following oral administration (mouse, rat and dog 1.0 mg/kg).
Enpatoran hydrochloride exhibits moderate half-lives (mouse 1.4, rat 5.0 and dog 13 h) due to high plasma clearance (1.4, 1.2 and 0.59 L/h/kg, respectively) combined with large volumes of distribution (2.7, 8.7 and 5.7 L/kg, respectively) following intravenous administration (mouse, rat and dog 1.0 mg/kg).

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Small Molecule Immuno-Oncology Compound Library  |  Drug Repurposing Compound Library  |  Antioxidant Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Targeted Diversity Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  C29  |  ODN 1018  |  TLR7 agonist 5  |  AN-3485  |  ODN 2088  |  TLR4/NF-κB/MAPK-IN-1  |  TLR9-IN-1  |  ODN 105871  |  MC-Val-Cit-PAB-Amide-TLR7 agonist 4  |  Monophosphoryl lipid A  |  β-D-Glucan  |  Poly (I:C):Kanamycin (1:1) (sodium)  |  ODN TTAGGG  |  Bropirimine  |  Polygalasaponin F  |  Chloroquine-d₅ (diphosphate)  |  DB-3-291  |  ODN 24888  |  ODN 2216  |  Agatolimod  |  BBIQ  |  UC-1V150  |  AZD8848  |  ODN 105870  |  CU-T12-9  |  TLR7/8 agonist 7  |  ODN 21158  |  TH1020  |  Lefitolimod

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤新的制藥及生命科學(xué)研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構(gòu)建立了長期的合作。